Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity (Q59236731)
Jump to navigation
Jump to search
article
Language | Label | Description | Also known as |
---|---|---|---|
English | Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity |
article |
Statements
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity (English)
Verity A Saunders
Phuong Dang
Jane Engler
Amity Venables
Stephanie Zrim
Kevin Lynch
Paul W Manley